

Amendment to Program Information

Credit Suisse International

AMENDMENT TO PROGRAM INFORMATION

Type of Information:	Amendment to Program Information
Date of Announcement:	21 January 2020
Issuer Name:	Credit Suisse International
Name and Title of Representative:	David Mathers Chief Executive Officer
Address of Head Office:	One Cabot Square, London E14 4QJ, UK
Telephone:	+44 (0)20 7888 8888
Contact Person:	Attorney-in-Fact: Eiichi Kanda, Attorney-at-law Chihiro Ashizawa, Attorney-at-law Yu Nimura, Attorney-at-law Clifford Chance (Gaikokuho Kyodo Jigyo) Palace Building, 3rd floor 1-1, Marunouchi 1-chome Chiyoda-ku, Tokyo 100-0005 Telephone: 81-3-6632-6600
Address of Website for Announcement:	https://www.jpx.co.jp/english/equities/products/tpbm/announcement/index.html
Information on initial Program Information:	
Date of Announcement:	20 August 2019
Scheduled Issuance Period:	21 August 2019 to 20 August 2020
Maximum Outstanding Issuance Amount:	Unlimited

This amendment is filed to update the information included in the Program Information dated 20 August 2019 (as amended on 21 October 2019 and 1 November 2019). This constitutes an integral part of the Program Information dated 20 August 2019 (as amended on 21 October 2019 and 1 November 2019) and shall be read together with it.



Credit Suisse International

Debt Issuance Programme (Unlimited Program Size)

This Supplement (the "**Supplement**") is supplemental to, and should be read in conjunction with, (i) the Listing Supplement dated 2 October 2015 (the "**Listing Supplement**") in respect of the debt issuance programme established by Credit Suisse International ("**CSi**" or the "**Issuer**") on 10 August 2006 for the issuance of securities of CSi (the "**Securities**") (as supplemented from time to time), (ii) any other documents incorporated by reference therein and (iii) in relation to any particular Securities, the Pricing Supplement relating to those Securities. Capitalised terms used in this Supplement but not defined herein shall have the meanings ascribed to them in the Listing Supplement.

Supplement to Listing Supplement dated 21 January 2020

DOCUMENTS INCORPORATED BY REFERENCE

The Listing Supplement and this Supplement should be read and construed in conjunction with the following document which shall be deemed to be incorporated in, and form part of, the Listing Supplement and the Supplement and supplement the section entitled "*Documents Incorporated by Reference*" of the Listing Supplement:

- (a) The registration document of the Issuer dated 6 December 2019 (the "**CSi Registration Document**") approved by the UK Listing Authority (as may be supplemented and/or replaced from time to time) is incorporated by reference in respect of CSi. The latest CSi Registration Document and any supplements thereto are available at <https://www.credit-suisse.com/ch/en/investment-banking/financial-regulatory/international.html>.
- (b) The annual and current reports, including interim financial information, and other relevant information of CSi, are incorporated by reference in respect of CSi and are available at <https://www.credit-suisse.com/ch/en/investment-banking/financial-regulatory/international.html> .

Copies of this Supplement will be available for inspection during normal business hours on any business day (except Saturdays, Sundays and legal holidays) at the offices of the Paying Agents. In addition, copies of the documents incorporated by reference in this Supplement (and any document incorporated by reference therein) will be available free of charge during normal business hours on any business day (except Saturdays, Sundays and legal holidays) at the offices of the Paying Agents and at the registered office of the Issuer.

CREDIT SUISSE INTERNATIONAL

The information provided below has been extracted from the CSi Registration Document and is correct as of the date of this Supplement. The sections in the Listing Supplement entitled "Change", "Name and Addresses of Directors and Executives" and "Legal and Arbitration Proceedings" shall be replaced with the information below under the respectively corresponding headings.

Change

There has been no significant change in the financial position of CSi since 30 June 2019.

There has been no material adverse change in the prospects of CSi since 31 December 2018.

There has been no significant change in the financial performance of CSi since 30 June 2019 to 8 January 2020.

Please see the "Risk Factors" section of the CSi Registration Document (pages 5 to 14) which discloses the principal risks to the Issuer.

Names and Addresses of Directors and Executives

The business address of the members of the Board of Directors is One Cabot Square, London E14 4QJ.

The current members of the Board of Directors, their role within CSi and their principal activities outside CSi, if any, are as follows:

Board Member	External Activities
John Devine (Non-Executive Chair)	<ul style="list-style-type: none"> ○ Independent member and Chair of the Board of Directors, Chair of the Nomination Committee, Interim Chair of the Risk Committee and Member of the Conflicts Committee of the Issuer and Credit Suisse Securities (Europe) Limited. ○ Mr. Devine is also <ul style="list-style-type: none"> ▪ Non-Executive Director, Chair of Audit Committee, Member of Risk Committee and Remuneration Committee of Standard Life Aberdeen PLC; and ▪ Non-Executive Director, Chair of Audit Committee, Member of Risk Committee and Nominations Committee of Citco Custody (UK) Ltd and Citco Custody Holding Ltd Malta.
Paul Ingram	<ul style="list-style-type: none"> ○ Managing Director in the CRO division of the Issuer. ○ Mr. Ingram is also Chief Risk Officer of the Issuer and Credit Suisse Securities (Europe) Ltd. ○ Member of the Board of Directors of the Issuer, Credit Suisse Securities (Europe) Limited and Credit Suisse AG (London Branch).
Christopher Horne	<ul style="list-style-type: none"> ○ Managing Director in the CFO division and Chair of the Disclosure Committee of the Issuer.

	<ul style="list-style-type: none"> ○ Mr. Horne is also Deputy CEO of the Issuer and Credit Suisse Securities (Europe) Ltd. ○ Member of the Board of Directors of the Issuer, Credit Suisse Securities (Europe) Limited, Credit Suisse AG (London Branch), Credit Suisse Investment Holdings (UK) and Credit Suisse Investments (UK).
Alison Halsey (Non-Executive)	<ul style="list-style-type: none"> ○ Independent member of the Board of Directors, Chair of the Audit Committee and the Conflicts Committee and Member of the Risk Committee, the Nomination Committee and the Advisory Remuneration Committee of the Issuer and Credit Suisse Securities (Europe) Limited. ○ Ms. Halsey is also: <ul style="list-style-type: none"> ▪ Non-executive Director and Member of the Risk & Compliance; and Nominations Committees and Chair of the Audit Committee of Aon UK Limited.
David Mathers (CEO)	<ul style="list-style-type: none"> ○ Managing Director in the CFO division of Credit Suisse AG. ○ Mr. Mathers is also CEO of the Issuer and Credit Suisse Securities (Europe) Limited and CFO of Credit Suisse AG. ○ Member of the Board of Directors of the Issuer and Credit Suisse Securities (Europe) Limited. ○ Member of the Executive Board of Credit Suisse AG and Credit Suisse Group AG.
Caroline Waddington	<ul style="list-style-type: none"> ○ Managing Director in the CFO division of the Issuer. ○ Ms. Waddington is also CFO for Credit Suisse UK Regulated Entities including the Issuer and Chair of the UK Pension Committee. ○ Member of the Board of Directors of the Issuer, Credit Suisse Securities (Europe) Limited, Credit Suisse AG (London Branch), Credit Suisse Investment Holdings (UK) and Credit Suisse Investments (UK). ○ Ms. Waddington is a member of the Board of Directors of: <ul style="list-style-type: none"> ▪ NameCo (No.357) Limited; ▪ Roffey Park Institute Limited, and a member of the Audit & Risk Committee; and ▪ Brook House (Clapham Common) Management Company Limited.
Jonathan Moore	<ul style="list-style-type: none"> ○ Managing Director in the Fixed Income Department within the Investment Banking Division of the Issuer. ○ Mr. Moore is also Head of Global Credit Products in EMEA and Senior Manager for Credit & Client in the UK. ○ Member of the Board of Directors of the Issuer and of Credit Suisse Securities (Europe) Limited.
Michael Dilorio	<ul style="list-style-type: none"> ○ Managing Director in the Global Markets division of the Issuer.

	<ul style="list-style-type: none"> ○ Mr. Dilorio is also Head of EMEA Equities which includes Cash Equities, Syndicate, Convertibles, Prime Services and Equity Derivatives. ○ Member of the Board of Directors of the Issuer and Credit Suisse Securities (Europe) Limited.
Andreas Gottschling (Non-Executive)	<ul style="list-style-type: none"> ○ Independent member of the Board of Directors, Chair of the Advisory Remuneration Committee and Acting Chair of the Risk Committee and Member of the Nominations Committee of the Issuer and Credit Suisse Securities (Europe) Limited. ○ Mr. Gottschling is also a member of the Board of Directors, the Audit Committee and the Governance & Nominations Committee, and Chair of the Risk Committee of Credit Suisse AG and Credit Suisse Group AG.
Nicola Kane	<ul style="list-style-type: none"> ○ Managing Director in the COO division of the Issuer. ○ Ms. Kane is also Global Head of Group Operations and Co-Head of Operations Technology and Solutions Delivery. ○ Member of the Board of Directors of the Issuer and Credit Suisse Securities (Europe) Limited.
Debra Jane Davies (Non-Executive)	<ul style="list-style-type: none"> ○ Independent member of the Board of Directors, Member of the Audit Committee, Nomination Committee and the Advisory Remuneration Committee of the Issuer and Credit Suisse Securities (Europe) Limited. ○ Ms. Davies is also: <ul style="list-style-type: none"> ▪ Non-Executive Director and Member of the Risk Committee of AXA UK plc; Non-Executive Director of AXA Insurance UK plc and AXA PPP Healthcare Limited.

Pages 1 to 7 of the 2019 CSi H1 Interim Report (as defined in the CSi Registration Document) and pages 1 to 7 of the 2018 CSi Annual Report (as defined in the CSi Registration Document) provide further information on the Issuers Board of Directors.

Legal and Arbitration Proceedings

During the period of 12 months ending on the date of the CSi Registration Document, there have been no governmental, legal or arbitration proceedings which may have, or have had in the recent past, significant effects on the financial position or profitability of the Issuer, and the Issuer is not aware of any such proceedings being either pending or threatened, except as disclosed in (i) the 2018 CSi Annual Report (as defined in the CSi Registration Document) under the heading "Contingent Liabilities and Other Commitments" (Note 39 to the consolidated financial statements of the Issuer) on pages 120 to 121, and (ii) the 2019 CSi H1 Interim Report (as defined in the CSi Registration Document) under the heading "Contingent Liabilities and Other Commitments" (Note 23 to the consolidated financial statements of the Issuer) on page 43, as updated by the following:

- On 6 September 2019, the third former Credit Suisse employee indicted by the United States Attorney for the Eastern District of New York pleaded guilty to accepting improper personal benefit in connection with financing transactions carried out with two Mozambique state enterprises, ProIndicus S.A. and Empresa Mocambiacana de Atum S.A. (EMATUM). Credit Suisse continues to cooperate with, and respond to requests from, regulatory and enforcement authorities in

connection with these transactions.

- Separately, certain Credit Suisse entities are defending civil proceedings brought by the Republic of Mozambique in the English High Court. The Republic of Mozambique seeks a declaration that the sovereign guarantee issued in connection with the ProIndicus loan syndication arranged and funded, in part, by a Credit Suisse subsidiary is void and also seeks unspecified damages alleged to have arisen in connection with the transactions involving ProIndicus and EMATUM, and a transaction in which Credit Suisse had no involvement with Mozambique Asset Management S.A.

Provision for litigation is disclosed in Note 28 to the consolidated financial statements on page 93 of the CSi 2018 Annual Report, as updated by the 2019 CSi H1 Interim Report (as defined in the CSi Registration Document).